Baxter International (NYSE:BAX) has reported better than expected Q1 Earnings and has raised its 2016 guided range above the Zacks Consensus Estimate of $0.28 - $0.30 per diluted share. The company’s adjusted income for the first quarter totaled to $199 million, or $0.36 per diluted share.

Net sales also grew by a modest 4% on a constant currency (cc) basis to $2.38 billion, despite the 5% hit from foreign exchange rates, thus again beating out the forecasted amount of $2.35 billion. Breaking down the markets, total sales from the U.S. reportedly improved by 5% year-over-year to $992 million. International Sales also increased to 4% at cc to $1.4 billion. However, factoring in forex rate volatility, international sales were said to have declined by 5% this year versus 2015.

Sales from hospital products grew to 4% while renal products improved by 5% at cc, earning Baxter International $1.5 billion and $898 million respectively. Greater sales of the SIGMA SPECTRUM infusion Pump and IV solutions in the U.S. helped to drive hospital product sales. Meanwhile, renal product revenues were caused by a higher demand for peritoneal dialysis products and continuous renal replacement therapies.

Adjusted earnings for 2016 are now expected to be estimated at $1.59 to $1.67 per diluted share for the entire year. Baxter also expects cc sales to grow to approximately 4%. Expected earnings from continuing operations, before special items, are forecasted in the range of $.35 to $0.40 cents per share.

Infusion pumps play an important role in hospitals by enabling healthcare providers to deliver fluids, medication, or nutrients into their patient’s circulatory system. AIV Inc. is dedicated to providing clinicians across the country with top-quality Infusion Pump solutions and services to ensure patient safety. We provide a vast line of IV pump parts, accessories and repair services for IV pump units such as Baxter. To learn more, visit http://aiv-inc.com/iv-pump-parts-service.html today.